Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
121-135 of 4028 results
RegeneRx enrolls first patients in phase 3 US dry eye clinical trial with RGN-259
RegeneRx Biopharmaceuticals has enrolled the first patient in a Phase 3 clinical trial (ARISE-2 trial) with RGN-259 (Thymosin beta 4), its sterile, preservative-free eye drop formulation developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), besides other corneal disorders.
Contract Research & Services > Clinical Trials > News
FDA lifts partial clinical hold on Adaptimmune's study of T-cell therapy in MRCLS
By PBR Staff Writer
The US Food and Drug Administration (FDA) has removed the partial clinical hold on Adaptimmune Therapeutics’ planned study of NY ESO specific peptide enhanced affinity receptor (SPEAR) T-cell therapy in Myxoid/round cell liposarcoma (MRCLS).
Contract Research & Services > Clinical Trials > News
Seattle Genetics, Takeda complete enrollment in phase 3 trial of ADCETRIS in frontline mature T-cell lymphoma
Seattle Genetics and Takeda Pharmaceutical Company have completed patient enrollment in the ECHELON-2 clinical trial, assessing ADCETRIS (Brentuximab Vedotin) in frontline mature T-cell lymphoma.
Contract Research & Services > Clinical Trials > News
Biogen and Ionis’ spinal muscular atrophy treatment meets primary endpoint in phase 3 study
By PBR Staff Writer
Biogen and Ionis Pharmaceuticals said that Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), has met the primary endpoint in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Onxeo unveils encouraging results from preclinical studies of Livatag in pancreatic cancer
Biopharmaceutical firm Onxeo has announced encouraging results from a series of preclinical studies evaluating Livatag interest for pancreatic cancer.
Contract Research & Services > Clinical Trials > News
Sanofi Genzyme starts phase 3 trial of second-generation enzyme replacement therapy for Pompe disease
Sanofi Genzyme, the specialty care global business unit of Sanofi, has started a pivotal Phase 3 clinical trial named COMET for the investigational therapy neoGAA for Pompe Disease.
Contract Research & Services > Clinical Trials > News
Mereo BioPharma reports positive outcome of phase 1 drug interaction study with acumapimod
UK-based Mereo BioPharma Group has reported positive results of its Phase 1 drug interaction study with acumapimod, the active compound in its p38 MAP kinase inhibitor BCT-197.
Contract Research & Services > Clinical Trials > News
Aurinia unveils plans for single phase III trial for voclosporin to treat lupus nephritis
Aurinia Pharmaceuticals has unveiled its plans for a single phase III clinical trial for voclosporin in the treatment of lupus nephritis (LN).
Contract Research & Services > Clinical Trials > News
Baxter starts phase 3 trial of new therapy for acute kidney injury
By PBR Staff Writer
Baxter International has initiated a phase 3 clinical trial of an investigational drug combining a citrate anticoagulant and renal replacement solution.
Contract Research & Services > Clinical Trials > News
Acadia starts phase II study of pimavanserin in Alzheimer’s disease agitation
Acadia Pharmaceuticals has started SERENE, a Phase II study with pimavanserin for the treatment of agitation in patients with Alzheimer’s disease (AD Agitation).
Contract Research & Services > Clinical Trials > News
Eisai starts two phase III studies for antiepileptic drug perampanel
Eisai has started two phase III clinical studies for its in-house-discovered antiepileptic drug (AED) perampanel (generic name: perampanel hydrate, product name: Fycompa) as adjunctive therapy in pediatric patients with partial-onset seizures or primary generalized tonic-clonic seizures (Study 311) and in patients with seizures associated with Lennox-Gastaut syndrome (LGS, Study 338).
Contract Research & Services > Clinical Trials > News
ProQR's QR-010 proof of concept CF study meets primary endpoint
ProQR Therapeutics announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function in a cohort of homozygous ∆F508 cystic fibrosis (CF) patients.
Contract Research & Services > Clinical Trials > News
FDA places partial hold on AstraZeneca’s two cancer drug trials
By PBR Staff Writer
The US Food and Drug Administration (FDA) has placed a partial clinical hold on AstraZeneca’s two cancer drug trials over bleeding incidents.
Contract Research & Services > Clinical Trials > News
Boehringer Ingelheim's Humira biosimilar candidate succeeds in rheumatoid arthritis study
By PBR Staff Writer
Boehringer Ingelheim’s adalimumab biosimilar candidate has demonstrated similar efficacy and safety profile to AbbVie’s Humira in pivotal phase III study in patients with active rheumatoid arthritis (RA).
Contract Research & Services > Clinical Trials > News
OncoGenex unveils positive survival results from Apatorsen phase 2 trial in metastatic bladder cancer
OncoGenex Pharmaceuticals has unveiled positive survival results from the final analysis of the Phase 2 Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.
Contract Research & Services > Clinical Trials > News
121-135 of 4028 results